Stock listing
A2P200 Stock Price, News, Filings & Events — Akeso, Inc.
Selected listing: A2P200 · LS · EUR · DE
This page tracks Akeso, Inc.'s A2P200:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2P200:LS. A2P200:LS is the stock-level entry point for investors researching Akeso, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2P200:LS
- Asset type
- Stock
- Market cap
- $10.99B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Akeso, Inc. A2P200:LS stock context
This page tracks Akeso, Inc.'s A2P200:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2P200:LS. A2P200:LS is the stock-level entry point for investors researching Akeso, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Akeso, Inc.
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
September 21, 2026
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
September 17, 2026
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
September 15, 2026
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
September 13, 2026
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
September 2, 2026
Research Akeso, Inc.
Akeso, Inc. investor report
Review AI stock analysis and investor report context for A2P200:LS.
Akeso, Inc. company profile
View the public company page for Akeso, Inc. on 6ix.
Akeso, Inc. news
Read company news and market updates connected to Akeso, Inc..
Akeso, Inc. investor events
Find investor webinars, events, and replay context for Akeso, Inc..
Alternate listings
9926:HKEX
HK · HKD
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
AKESF:OTC
US · USD
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:GETTEX
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:SWB
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
A2P200:LSX
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:TRADEGATE
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:DUS
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:FWB
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:HAM
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.
4RY:MUN
DE · EUR
Alternate listing for Akeso, Inc.; the primary context on this page is A2P200:LS.